Importance of Pre-Transplant Vaccination in Reducing Rotavirus Infection in Post-Transplant Patients

  • Hamza H Khan MedStar Georgetown University Hospital, Washington, DC
  • Ahmed R Alhabib MedStar Georgetown University Hospital, Washington, DC
  • Abdullah Karabala MedStar Georgetown University Hospital, Washington, DC
  • Khalid M Khan MedStar Georgetown University Hospital, Washington, DC
  • Stuart S Kaufman MedStar Georgetown University Hospital, Washington, DC
  • Nada A Yazigi MedStar Georgetown University Hospital, Washington, DC
Keywords: Rotavirus infection, Rotavirus vaccination, Transplant patients, Economic burden, Health burden

Abstract

Rotavirus is a highly contagious member of the Reoviridae family. It is the most common cause of diarrhea in the pediatric population. In this review, all the transplant pediatric patients admitted to our institute from January-May 2017 were reviewed. The inclusion criteria of our study included a chief complaint of diarrhea and a positive test for rotavirus with no confounding cause for the symptoms or for the admission. Based on the available data it can be concluded that administration of rotavirus vaccine in patients with intestinal failure prior to intestinal transplant can significantly decrease the incidence of rotavirus enteritis. Since the maximum recommended age for last dose of either vaccine is 32 weeks, therefore early vaccination as part of routine immunization is very important. This will improve the overall morbidity and mortality as well as the health-related financial burden on the hospital and economy.

References

1. Uzoma EB, Chukwubuikem C, Omoyibo E, Tagbo O. Rota virus genotypes and the clinical severity of Diarrhoea among children under 5 years of age. Niger Postgrad Med J. 2016; 23:1-5.
2. Cui H, Bai S, Huo Z, Li J, Sun J, An X. A cluster of rotavirus enteritis in pediatric liver recipients. Transpl Infect Dis. 2015; 17(3):477-80.
3. Grosfeld JK, Rescorla FJ, West KW. Short bowel syndrome in infancy and childhood: analysis of survival in 60 patients. Am J Surg. 1986; 151:41–6.
4. West KW, Rescorla FJ, Grosfeld JL, Vane DW. Pneumatosis intestinalis in children beyond the neonatal period. J Pediatr Surg. 1989; 24:818–22.
5. Anagnostopoulos D, Valioulis J, Sfougaris D, et al. Morbidity and mortality of short bowel syndrome in infancy and childhood. Eur J Pediatr Surg. 1991; 1:273–6.
6. Stelzmueller I, Wiesmayr S, Swenson BR, et al. Rotavirus enteritis in solid organ transplant recipients: an underestimated problem? Transpl Infect Dis. 2007; 9(4):281-5.
7. Valentini D, Ianiro G, Di Bartolo I, et al. Hospital-acquired rotavirus and norovirus acute gastroenteritis in a pediatric unit, in 2014-2015. J Med Virol. 2017; 89(10):1768-1774.
8. Yin Y, Metselaar HJ, Sprengers D, Peppelenbosch MP, Pan Q. Rotavirus in Organ Transplantation: Drug-Virus-Host Interactions. Am J Transplant. 2015; 15(3):585-93.
9. Centers for Disease Control and Prevention (CDC) Rotavirus vaccination coverage among infants aged 5 months - immunization information system sentinel sites, United States, June 2006–June 2009. MMWR Morb Mortal Wkly Rep. 2010; 59:521–4.
10. Ghazanfar H, Naseem S, Ghazanfar A, Haq S. Rotavirus vaccine--a new hope. J Pak Med Assoc. 2014; 64(10):1211-6.
11. Cortes JE, Curns AT, Tate JE, et al. Rotavirus vaccine and health care utilization for diarrhea in U.S. children. N Eng J Med. 2011; 365:1108–17.
12. Desai R, Haberling D, Holman RC, et al. Impact of rotavirus vaccine on diarrhea-associated disease burden among American Indian and Alaska native children. Pediatrics. 2012; 129:e907–13.
13. Curns AT, Steiner CA, Barrett M, et al. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J Infect Dis. 2010; 201:1617–24.
14. Krishnarajah G, Kageleiry A, Korves C, Lefebvre P, Duh MS. Public health impact of Rotarix vaccination among commercially insured children in the United States. Vaccine. 2017; 35(37):5065-5072.
15. Centers for Disease Control and Prevention (CDC) Progress in the introduction of rotavirus vaccine – Latin America and the Caribbean, 2006–2010. MMWR Morb Mortal Wkly Rep. 2011; 60:1611–4.
16. Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomized, double-blind, placebo-controlled trial. Lancet. 2010; 376:606–14.
17. World Health Organization (WHO). Immunization, Vaccines and Biologicals: Rotavirus. 2010. Available at: http://www.who.int/immunization/topics/rotavirus/en/ (Accessed: Feb 19, 2018).
18. Javid PJ, Sanchez SE, Jacob S, McNeal MM, Horslen SP, Englund JA. The Safety and Immunogenicity of Rotavirus Vaccination in Infants with Intestinal Failure. J Pediatric Infect Dis Soc. 2014; 3(1):57-65.
19. Fang AY, Tingay DG. Early observations in the use of oral rotavirus vaccination in infants with functional short gut syndrome. J Paediatr Child Health. 2012; 48(6):512-6.
Published
2018-11-14
Section
Original Article